[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2012078982A3 - Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells - Google Patents

Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells Download PDF

Info

Publication number
WO2012078982A3
WO2012078982A3 PCT/US2011/064152 US2011064152W WO2012078982A3 WO 2012078982 A3 WO2012078982 A3 WO 2012078982A3 US 2011064152 W US2011064152 W US 2011064152W WO 2012078982 A3 WO2012078982 A3 WO 2012078982A3
Authority
WO
WIPO (PCT)
Prior art keywords
xzh
stat3 phosphorylation
interleukin
hepatocellular carcinoma
carcinoma cells
Prior art date
Application number
PCT/US2011/064152
Other languages
French (fr)
Other versions
WO2012078982A2 (en
Inventor
Chenglong Li
Jiayuh Lin
Hong Wang
Original Assignee
The Ohio State University
Nationwide Children's Hospital, Inc.
Miami University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Ohio State University, Nationwide Children's Hospital, Inc., Miami University filed Critical The Ohio State University
Publication of WO2012078982A2 publication Critical patent/WO2012078982A2/en
Publication of WO2012078982A3 publication Critical patent/WO2012078982A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides compounds, compositions of matter and methods related to XZH-5 and related chemical therapeutics. The inhibitory effects of a series of small molecules structurally related to XZH-5 on STAT3 phosphorylation is disclosed, as are the results of that inhibition, including induction of apoptosis, reduction of colony forming ability, inhibition of IL-6- induced STAT3 phosphorylation, and nuclear translocation and STAT3 DNA binding activity.
PCT/US2011/064152 2010-12-09 2011-12-09 Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells WO2012078982A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42134110P 2010-12-09 2010-12-09
US61/421,341 2010-12-09

Publications (2)

Publication Number Publication Date
WO2012078982A2 WO2012078982A2 (en) 2012-06-14
WO2012078982A3 true WO2012078982A3 (en) 2012-09-07

Family

ID=46207764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/064152 WO2012078982A2 (en) 2010-12-09 2011-12-09 Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells

Country Status (1)

Country Link
WO (1) WO2012078982A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078982A2 (en) * 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
CN113939300A (en) 2019-04-05 2022-01-14 凯麦拉医疗公司 STAT degradants and uses thereof
KR102199141B1 (en) * 2019-05-03 2021-01-06 사회복지법인 삼성생명공익재단 Diagnostic biomarker of colorectal cancer using cytokine-induced STAT phosphorylation in peripheral blood immune cells by flow cytometry

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073650A2 (en) * 2003-02-20 2004-09-02 University Of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
US20090069420A1 (en) * 2006-05-19 2009-03-12 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of STAT3 with anti-tumor activity
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2012078982A2 (en) * 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073650A2 (en) * 2003-02-20 2004-09-02 University Of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
US20090069420A1 (en) * 2006-05-19 2009-03-12 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of STAT3 with anti-tumor activity
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2012078982A2 (en) * 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM 21 July 2009 (2009-07-21), "2-[[(2-phenylcarbamoylamino)acetyl]amino]acetic acid", retrieved from http://pubchem.ncbi.nlm.nih.gov/summarylsummary.cgi?cid=43354399&loc=eç rcs accession no. 3354399 *

Also Published As

Publication number Publication date
WO2012078982A2 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
TW201711676A (en) Ferric citrate dosage forms
WO2011111880A9 (en) Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3
IN2015DN03795A (en)
ZA201208222B (en) Process including hydrogenolysis of biomass followed by dehydrogenation and aldol condensation to produce alkanes
WO2014080291A3 (en) Biaryl derivatives as bromodomain inhibitors
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
EP2244714A4 (en) Use of picoplatin and bevacizumab to treat colorectal cancer
IN2014DN09370A (en)
EP2440221A4 (en) Composition used to prevent and treat red blood cell coagulation
WO2013188813A3 (en) Novel therapeutics for brain cancer
MX2013008192A (en) Bace-2 inhibitors for the treatment of metabolic disorders.
MX363579B (en) PHARMACEUTICAL COMPOSITIONS and METHODS.
ZA201307425B (en) Bio-augmentation composition and use thereof for improving efficiency of effluent treatment in hydrocarbon processing plant
WO2012038504A3 (en) Breast cancer therapeutics
EP2521784A4 (en) Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
EP2626071A4 (en) Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction
EP2930254A4 (en) Stainless steel-clad steel plate having exceptional corrosion resistance to seawater
WO2012125981A3 (en) Raf kinase inhibitors
WO2012167028A9 (en) Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
WO2013169631A3 (en) Wnt protein signalling inhibitors
HK1191557A1 (en) Composition adipose tissue-derived secretions for use in the topical treatment or prevention of acne
WO2012078982A3 (en) Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
BR112012002353A2 (en) use of nkg2d inhibitors to treat cardiovascular and metabolic diseases such as type 2 diabetes
WO2012134172A3 (en) Composition containing, as an active ingredient, an ethyl acetate fraction of schisandra chinensis baill, or wuweizisu c separated from the fraction, for preventing or treating obesity
MX2013002261A (en) Substituted n-phenethyltriazoloneacetamides and use thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11846099

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 16/08/2013 )

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 16/08/2013)

122 Ep: pct application non-entry in european phase

Ref document number: 11846099

Country of ref document: EP

Kind code of ref document: A2